Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116052 | 0.78 | DRD2 (0.51) | MEN1KMT2ACHRM4BCHE | |
| SCHEMBL3217075 | 0.77 | BCHE (0.37) | PTGDR2GRIN2BTBXA2RBCHE | |
| SCHEMBL3205175 | 0.77 | BCHE (0.37) | PTGDR2GRIN2BTBXA2RBCHE | |
| SCHEMBL4179654 | 0.76 | BCHE (0.38) | MEN1KMT2AGRIN2BTBXA2RBCHE | |
| SCHEMBL4193805 | 0.75 | GRIN2B (0.38) | PTGDR2MEN1KMT2AGRIN2BTBXA2R | |
| SCHEMBL4190993 | 0.74 | GRIN2B (0.39) | MEN1KMT2AGRIN2BTBXA2RBCHE | |
| SCHEMBL5115681 | 0.69 | TACR3 (0.52) | — | |
| SCHEMBL5116054 | 0.66 | BCHE (0.47) | MEN1KMT2ABCHE | |
| SCHEMBL3681668 | 0.66 | PTGDR2 (0.46) | PTGDR2MEN1KMT2ATBXA2R | |
| SCHEMBL20399604 | 0.66 | GRIN2B (0.46) | GRIN2BBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | PTGDR2 297/4885MEN1 1810/4885KMT2A 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.